^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
WSD0628
i
Other names: WSD0628
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Wayshine Biopharm
Drug class:
ATM kinase inhibitor, Radiosensitiser
Related drugs:
3ms
ATM inhibitors in cancer radiotherapy: Mechanisms, clinical development, and future directions. (PubMed, Eur J Med Chem)
Inhibitors such as KU-55933, KU-60019, and AZD1390 have shown the potential to sensitize cancer cells to radiotherapy by impairing DNA repair, thereby enhancing treatment efficacy...Currently, none have gained approval from the FDA or EMA, but six candidates, AZD1390, AZD0156, ZN-B-2262, SYH2051, WSD0628 and M3541 are in clinical trials, often as adjuncts to radiotherapy or in combination with PARP inhibitors. Their safety and effectiveness, however, are still under investigation. This review synthesizes ATM's dual roles and the therapeutic promise of targeting ATM in cancer radiotherapy.
Review • Journal • PARP Biomarker
|
CHEK2 (Checkpoint kinase 2) • CHEK1 (Checkpoint kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
AZD1390 • KU-55933 • AZD0156 • M3541 • WSD0628
4ms
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma (clinicaltrials.gov)
P1, N=94, Recruiting, Mayo Clinic | N=67 --> 94
Enrollment change
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type
|
WSD0628
almost2years
Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=67, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type
|
WSD0628
almost2years
Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=67, Not yet recruiting, Mayo Clinic | Trial completion date: Oct 2028 --> Feb 2029 | Trial primary completion date: Oct 2027 --> Feb 2028
Trial completion date • Trial primary completion date • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type
|
WSD0628
2years
Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=67, Not yet recruiting, Mayo Clinic | Trial primary completion date: Oct 2028 --> Oct 2027
Trial primary completion date • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type
|
WSD0628
over2years
Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=67, Not yet recruiting, Mayo Clinic
New P1 trial • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type
|
WSD0628
Share via
